Crispr Therapeutics AG (CRSP)
NASDAQ · Healthcare
Crispr Therapeutics AG Shareholder Equity 2015–2025
Crispr Therapeutics AG annual/quarterly shareholder equity history from 2015 to 2025. Shareholder equity represents the net worth of a company, calculated as total assets minus total liabilities.
- Crispr Therapeutics AG shareholder equity for the quarter ending December 31, 2025 were 1.92B, a 0.53% decrease year-over-year.
- Crispr Therapeutics AG shareholder equity for 2025 were 1.92B, a 0.53% decrease from 2024.
- Crispr Therapeutics AG shareholder equity for 2024 were 1.93B, a 2.62% increase from 2023.
- Crispr Therapeutics AG shareholder equity for 2023 were 1.88B, a 0.39% increase from 2022.
- Crispr Therapeutics AG shareholder equity for 2022 were 1.88B.
Shareholder Equity
QUARTERLY · $B
YOY QUARTERLY GROWTH · %
| Crispr Therapeutics AG Annual Shareholder Equity (Millions of US $) | |
|---|---|
| 2025 | $1,922 |
| 2024 | $1,932 |
| 2023 | $1,883 |
| 2022 | $1,875 |
| 2021 | $2,399 |
| 2020 | $1,664 |
| 2019 | $939 |
| 2018 | $392 |
| 2017 | $188 |
| 2016 | $233 |
| 2015 | $-29 |
| Crispr Therapeutics AG Quarterly Shareholder Equity (Millions of US $) | |
|---|---|
| 2025-12-31 | $1,922 |
| 2024-12-31 | $1,932 |
| 2023-12-31 | $1,883 |
| 2022-12-31 | $1,875 |
| 2021-12-31 | $2,399 |
| 2020-12-31 | $1,664 |
| 2019-12-31 | $939 |
| 2018-12-31 | $392 |
| 2017-12-31 | $188 |
| 2016-12-31 | $233 |
| 2015-12-31 | $-29 |
Crispr Therapeutics AG Shareholder Equity — FAQ
Crispr Therapeutics AG (CRSP) shareholder equity over the last 11 years — annual and quarterly figures with year-over-year growth and charts.
Where can I see CRSP's shareholder equity history?
The chart and table above show Crispr Therapeutics AG's shareholder equity by year and by quarter, including the growth rate.